


Supplementary information, Fig. S7



Supplementary information, Fig. S7. Signatures of BTN3A3 and LSECTin abundance in the breast cancer

(a) *Btn3a3* mRNA expression in ER⁺ and ER⁻ samples from the TCGA data set (ER⁺ n = 769; ER⁻ n = 227).

(b) Real-time PCR analysis showing *Btn3a3* expression with cDNAs from ER⁺ patients (n=12, black) and ER⁻ patients (n = 17, red) as templates.

(c) Kaplan-Meier survival curve of breast cancer patients from the TCGA data set (For ER⁺ samples, BTN3A3^{low}: 60%, n = 462, BTN3A3^{high}: 40%, n = 307; for ER⁻ samples, BTN3A3^{low}: 60%, n = 137, BTN3A3^{high}: 40%, n = 90).

(d) *Btn3a3* mRNA expression in PR⁺ and PR⁻ samples from the TCGA data set (PR⁺ n = 667; PR⁻ n = 325).

(e) *Btn3a3* mRNA expression in HER2⁺ and HER2⁻ samples from the TCGA data set (HER2⁺ n = 156; HER2⁻ n = 537).

(f,g) Kaplan-Meier survival curve of breast cancer patients from the TCGA data set (For non-TNBC samples, BTN3A1^{low}/BTN3A2^{low}: 60%, n = 496, BTN3A1^{high}/BTN3A2^{high}: 40%, n = 328; for TNBC samples, BTN3A1^{low}/BTN3A2^{low}: 60%, n = 64, BTN3A1^{high}/BTN3A2^{high}: 40%, n = 41).

(h) Correlation between *Lsectin* expression and TAM-associated gene expression in human breast cancer samples from the TCGA data set (non-TNBC n = 824; TNBC n = 105), GSE76275 (non-TNBC n = 198; TNBC n = 65).

Data are presented as the mean \pm SD. **P* < 0.05, ***P* < 0.01, ****P* < 0.001 (unpaired Student's t test for a, b, d, e).